Provision of Testing Services and Sample Analysis as part of the National Immunisation Programme Study

Concepts

• laboratory services
• national immunisation programme study
• salisbury
• dhsc
• national immunisation programme
• part of the national immunisation programme study
• provision of testing services
• sample analysis
• sole supplier of t cell testing
• different studies

Location

United Kingdom:

Description

PHE has been tasked by DHSC to urgently undertake a study to evaluate the immune response following COVID-19 vaccines as part of the National Immunisation Programme. This has been identified as a high national public health priority and a key aspect of this study requires taking 2000 samples for cellular work over a 24-month period. The UK Vaccines Taskforce have selected Oxford Immunotec as the sole supplier of T cell Testing for SARS-CoV-2 specific responses as part of the new COVID vaccine trials. Aligning PHE's study with this decision will ensure that it is consistent with the other vaccine studies performed within the UK, providing for comprehensive comparison and analysis to be carried out across all the different studies.

Total Quantity or Scope

Oxford Immunotec will provide testing services and sample analysis to assist PHE in its evaluation of immune responses following COVID-19 vaccines used in the National Immunisation Programme.

Award Detail

Award Criteria

CPV Codes

• 71900000 - Laboratory services

Legal Justification

The justification to source these services from Oxford Immunotec is to enable PHE to adhere with the decision made by the UK Vaccines Taskforce who selected Oxford Immunotec as the sole supplier of T cell Testing for SARS-CoV-2 specific responses as part of the new COVID vaccine trials. Oxford Immunotec was chosen as a result of the competitive process for its expertise in T cell measurement and its unique ability to provide T-SPOT® technology, the only globally regulated ELISPOT platform - which is currently being used clinically for identifying T cells made in response to another respiratory pathogen responsible for Tuberculosis. Aligning with this verdict will ensure that the National Immunisation Programme being carried out by PHE is consistent with the other vaccine studies performed within the UK, providing for comprehensive comparison and analysis to be carried out across all the different studies. The Vaccines Taskforce has emphasised that it is important to be able to assess the different vaccines head-to-head and employing Oxford Immunotec's T-SPOT technology will measure the magnitude of the SARS-CoV-2 protein-specific T cell response of different vaccine candidates for cross-comparisons.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **